Omniscope

omniscope.ai ↗ ·Barcelona ·Seed

Omniscope is a TechBio company that combines high-resolution single-cell immune sequencing (T-cell/B-cell receptor repertoires) with AI to build an immune databank that maps 'immune age', tracks clonal dynamics and identifies cellular drivers of chronic disease and ageing. Its products include osLifetime, osLongevity, osSports and a clinical Immune Portal, aimed at immuno-oncology, longevity and sports performance. Founded in 2020 and headquartered in Barcelona with operations in Malta and a US entity in Delaware, it raised roughly $8M in a seed round announced in February 2025 and works with partners such as CNAG, Barça Innovation Hub, Fox Chase Cancer Center, GSK, Google Cloud and NVIDIA Inception.

Founded

2020

Founders

Total funds raised

€1.8M+

SectorsHealthtech & Bio, AI & Data, Biotech, Immunology, Diagnostics, Longevity Start-up MapHealthtech & Bio › Diagnostics & precision medicine testing

Suggest a correction

Founders

Holger Heyn

Co-Founder & Chief Scientific Officer

Lynnette Ang

Co-Founder & Chief Growth Officer

Vijay Vaswani

Co-Founder & CEO

Global models 3

Adaptive Biotechnologies

United States · www.adaptivebiotech.com ↗

Sequences T-cell and B-cell receptor repertoires at scale to build an immune map, which it sells as diagnostics, research services and drug-discovery partnerships.

~$400MComparable

Immunai

United States · www.immunai.com ↗

Combines single-cell immune profiling with AI to build an immune atlas that finds disease drivers, sold through pharma partnerships in immuno-oncology and immunology.

~$295MComparable

AbCellera

Canada · www.abcellera.com ↗

Screens single immune cells and uses AI to mine B-cell repertoires, then earns partnership fees and royalties, a close match to Omniscope's repertoire-plus-AI TechBio model.

~$105MComparable